Publicacións en colaboración con investigadores/as de Hospital Clinic Barcelona (43)

2023

  1. Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer (npj Breast Cancer, (2021), 7, 1, (1), 10.1038/s41523-020-00208-2)

    npj Breast Cancer

2022

  1. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

    Science Advances, Vol. 8, Núm. 20

2021

  1. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease

    Journal of Clinical Investigation, Vol. 130, Núm. 9, pp. 4871-4887

  2. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

  3. Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation

    Clinical Cancer Research, Vol. 26, Núm. 6, pp. 1432-1448

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

  3. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

  4. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

    Oncologist, Vol. 24, Núm. 5, pp. 603-611

  5. Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)

    Nature Cell Biology

  3. Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii90

2017

  1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

  2. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  3. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

    Cancer Research, Vol. 77, Núm. 9, pp. 2213-2221

  4. Physical activity and breast cancer risk by pathological subtype

    Gynecologic Oncology, Vol. 144, Núm. 3, pp. 577-585

2015

  1. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795

  2. Lower breast cancer risk among women following the World Cancer Research Fund and American Institute for Cancer Research lifestyle recommendations: Epigeicam case-control study

    PLoS ONE, Vol. 10, Núm. 5